The emerging evidence synthesis tools: Actively Living Network Meta-Analysis

Session: 

Oral session: Overviews of reviews and network meta-analysis (2)

Date: 

Monday 17 September 2018 - 14:40 to 15:00

Location: 

Fintry Auditorium

All authors in correct order:

Nikolakopoulou A1, Trelle S2, Egger M1, Salanti G1
1 Institute of Social and Preventive Medicine, University of Bern, Switzerland
2 Clinical Trial Unit, University of Bern, Switzerland
Presenting author and contact person

Presenting author:

Adriani Nikolakopoulou

Contact person:

Adriani Nikolakopoulou
Abstract text
Background: Network meta-analyses (NMA) are increasingly becoming the norm in evidence synthesis for comparative effectiveness research, and living systematic reviews have been proposed as a mean to providing timely evidence. The key feature of a living systematic review is the frequent update of the evidence with new studies as these become available. This process of updating could be improved by making specific recommendations about what sort of research is needed to improve the output of a living systematic review by identifying gaps in the evidence.

Objectives: We aim:
1) to introduce the concept of ‘Actively Living Network Meta-Analysis’(AL-NMA); a living NMA that actively makes specific suggestions about the need of further studies to answer the research question they address;
2) to present results from a survey among trial methodologist to explore the acceptability of the paradigm shift that AL-NMA entails.

Methods: To present the potential and applicability of AL-NMA:
1) we compared the strength and speed of evidence accumulation using living NMA compared with living pairwise meta-analysis in 46 NMAs;
2) virtually, we designed a new study to resolve uncertainties about the efficacy of biologics in rheumatoid arthritis using data from an existing NMA as ‘historical data';
3) we conducted a survey of trial methodologists about their perceptions for NMA and their opinions about using NMA to design a new clinical trial.

Results: Living network meta-analysis had 20% greater chance of obtaining strong evidence against the null hypothesis compared with living pairwise meta-analysis. Using data from NMA resulted in a reduction of the required sample size by more than one-third compared with using data from pairwise meta-analysis. Three out of four participants of the survey were willing to consider definitely, or possibly, using NMA to design a new clinical trial.

Conclusions: AL-NMA can increase precision, timeliness and relevance in evidence synthesis; its adoption can help investigators, trialists, funders and regulators to make informed decisions about the best use of existing and the planning of new clinical trials.

Patient or healthcare consumer involvement: None involved.

Relevance to patients and consumers: 

Patients and consumers have not been involved in this research.